Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944792 | 1.00 | KMT2A (0.39) | KMT2ANPC1RAB9ABRD4TP53 | |
| SCHEMBL2944275 | 0.85 | BRD4 (0.41) | KMT2ANPC1RAB9ABRD4TP53 | |
| SCHEMBL2944277 | 0.85 | BRD4 (0.41) | KMT2ANPC1RAB9ABRD4TP53 | |
| SCHEMBL2951812 | 0.82 | POLB (0.41) | KMT2ANPC1RAB9A | |
| SCHEMBL2951809 | 0.82 | POLB (0.41) | KMT2ANPC1RAB9A | |
| SCHEMBL2943702 | 0.78 | NPY5R (0.46) | KMT2ANPC1RAB9ABRD4TP53 | |
| SCHEMBL2599858 | 0.78 | NPY5R (0.46) | KMT2ANPC1RAB9ABRD4TP53 | |
| SCHEMBL2945600 | 0.77 | BRD4 (0.39) | KMT2ABRD4TP53BTKSMN1; SMN2 | |
| SCHEMBL2945601 | 0.77 | BRD4 (0.39) | KMT2ABRD4TP53BTKSMN1; SMN2 | |
| SCHEMBL13780076 | 0.77 | PKM (0.38) | KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | KMT2A 2033/4885NPC1 4426/4885RAB9A 4692/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | KMT2A 1957/4885NPC1 4566/4885RAB9A 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.